Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials

By Higashijima Yoshiki   Tanaka Tetsuhiro   Nangaku Masaomi  

Expert Opinion on Drug Discovery, Vol. 8, Iss. 8, 2013-11 ,pp. : 965-976

Informa Healthcare

Access to resources Recommend Favorite

Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction

By  

Current Pharmaceutical Design, Vol. 20, Iss. 9, 2014-01 ,pp. : 1305-1310

Bentham Science Publishers

Access to resources Recommend Favorite

Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits hypoxia-induced neovasculogenesis through prolyl hydroxylase, von Hippel–Lindau-dependent pathway

By Li Ching-Hao   Liao Po-Lin   Yang Ya-Ting   Huang Shih-Hsuan   Lin Cheng-Hui   Cheng Yu-Wen   Kang Jaw-Jou  

Archives of Toxicology, Vol. 88, Iss. 3, 2014-03 ,pp. : 659-671

Springer Publishing Company

Access to resources Recommend Favorite

HIF prolyl hydroxylase inhibitors for anemia

By Muchnik Eugene   Kaplan Joshua  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 5, 2011-05 ,pp. : 645-656

Informa Healthcare

Access to resources Recommend Favorite

Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)

By  

Current Pharmaceutical Design, Vol. 12, Iss. 21, 2006-07 ,pp. : 2673-2688

Bentham Science Publishers

Access to resources Recommend Favorite